Uric acid and evolution

Rheumatology

Volumn 49, Issue 11, 2010, Pages 2010-2015

  Álvarez Lario, Bonifacio ^a   Macarrón Vicente, Jesús ^a  

^a HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

Author keywords

Antioxidants; Evolution; Gout; Hyperuricaemia; Neurodegenerative diseases; Neuroprotection; Oxidative stress; Salt ingestion; Uric acid; Uricase

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; PEROXYNITRITE; PURINE; REACTIVE OXYGEN METABOLITE; SODIUM CHLORIDE; URATE OXIDASE; URIC ACID;

ALCOHOL CONSUMPTION; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIOXIDANT ACTIVITY; BLOOD PRESSURE; DEGENERATIVE DISEASE; DIET; DRUG DOSE COMPARISON; GENE MUTATION; GOUT; HOMINID; HUMAN; HYPERTENSION; HYPERURICEMIA; HYPOTHESIS; INTELLIGENCE; INTELLIGENCE QUOTIENT; LIFE EXPECTANCY; LONGEVITY; MENTAL DEFICIENCY; NERVE CELL DIFFERENTIATION; NEUROPROTECTION; NONHUMAN; OBESITY; OXIDATIVE STRESS; PARKINSON DISEASE; PREVALENCE; PRIORITY JOURNAL; PROTEIN DEPLETION; PURINE METABOLISM; REVIEW; RISK FACTOR; SODIUM RESTRICTION; URIC ACID URINE LEVEL;

ANIMALS; ANTIOXIDANTS; BIOLOGICAL EVOLUTION; HUMANS; NEUROPROTECTIVE AGENTS; PRIMATES; PURINES; URATE OXIDASE; URIC ACID;

EID: 78649341901     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq204     Document Type: Review

References (60)

1. Richette P, Bardin T. Gout. Lancet 2010;375:318-28.
2. Riches PL, Wright AF, Ralston SH. Recent insights into the pathogenesis of hyperuricemia and gout. Hum Mol Genet 2009;18:R177-84.
3. Doherty M. New insights into the epidemiology of gout. Rheumatology 2009;48:ii2-8.
4. Feig DI, Kang D-H, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008;359:1811-21.
5. Annemans L, Spaepen E, Gaskin M et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis 2008;67:960-6.
6. Feig DI, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2009;360:540-1.
7. Perez-Ruiz F. Treating to target: a strategy to cure gout. Rheumatology 2009;48:ii9-14.
8. Vitart V, Rudan I, Hayward C et al. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet 2008; 40:437-42.
9. Johnson RJ, Rideout BA. Uric acid and diet-insights into epidemic of cardiovascular disease. N Engl J Med 2004; 350:1071-3.
10. Gibson T, Waterworth R, Hatfield P, Robinson G, Bremner K. Hyperuricaemia, gout and kidney function in New Zealand Maori men. Br J Rheumatol 1984;23:276-82.
11. Simmonds HA, McBride MB, Hatfield PJ, Graham R, McCaskey J, Jackson M. Polynesian women are also at risk for hyperuricaemia and gout because of a genetic defect in renal urate handling. Br J Rheumatol 1994;33: 932-7.
12. Hollis-Moffatt JE, Xu X, Dalbeth N et al. Role of the urate transporter SLC2A9 gene in susceptibility to gout in New Zealand Maori, Pacific Island and Caucasian case-control sample sets. Arthritis Rheum 2009;60:3485-92.
13. Klemp P, Stansfield SA, Castle B, Robertson MC. Gout is on the increase in New Zealand. Ann Rheum Dis 1997;56: 22-6.
14. Rider TG, Jordan KM. The modern management of gout. Rheumatology 2010;49:5-14.
15. Hayashi S, Fujiwara S, Noguchi T. Evolution of urate-degrading enzymes in animal peroxisomes. Cell Biochem Biophys 2000;32:123-9.
16. Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in human against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA 1981;78:6858-62.
17. Watanabe S, Kang DH, Feng L et al. Uric acid, hominoid evolution and the pathogenesis of salt-sensitivity. Hypertension 2002;40:355-60.
18. Johnson RJ, Kang DH, Feig D et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003;41:1183-90.
19. Varela-Echevarría A, Montes de Oca-Luna R, Barrera-Saldaña HA. Uricase protein sequences: conserved during vertebrate evolution but absent in humans. FASEB J 1988; 2:3092-6.
20. Oda M, Satta Y, Takenaka O, Takahata N. Loss of urate oxidase activity in hominoids and its evolutionary implications. Mol Biol Evol 2002;19:640-53.
21. Wu X, Muzny DM, Lee CC, Caskey CT. Two independent mutational events in the loss of urate oxidase during hominoid evolution. J Mol Evol 1992;34:78-84.
22. Jhonson RJ, Titte S, Cade JR, Rideout BA, Oliver WJ. Uric acid, evolution and primitive cultures. Semin Nephrol 2005;25:3-8.
23. Wu X, Wakamiya M, Vaishnav S et al. Hyperuricemia and urate nephropathy in urate oxidase-deficient mice. Proc Natl Acad Sci USA 1994;91:742-6.
24. Christen P, Peackock WC, Christen AE, Wacker WE. Urate oxidase in primate phylogenesis. Eur J Biochem 1970;12:3-5.
25. Kutzing MK, Firestein BL. Altered uric acid levels and disease states. J Pharmacol Exp Ther 2008;324:1-7.
26. Glantzounis G, Tsimoyiannis E, Kappas A, Galaris D. Uric acid and oxidative stress. Curr Pharm Des 2005;11: 4145-51.
27. Parmar MS. Uric acid and cardiovascular risk. N Engl J Med 2009;360:539.
28. Spitsin SV, Scott GS, Mikheeva T et al. Comparison of uric acid and ascorbic acid in protection against EAE. Free Radic Biol Med 2002;33:1363-71.
29. Sohal RS. Role of oxidative stress and protein oxidation in the aging process. Free Radic Biol Med 2002;33:37-44.
30. Jang YC, Pérez VI, Song W et al. Overexpression of Mn superoxide dismutase does not increase life span in mice. J Gerontol A Biol Sci Med Sci 2009;64:1114-25.
31. 2, and basal and maximum aerobic capacity. Mech Ageing Dev 1993;70: 177-99.
32. Zhang Y, Ikeno Y, Qi W et al. Mice deficient in both Mn superoxide dismutase and glutathione peroxidase-1 have increased oxidative damage and a greater incidence of pathology but no reduction in longevity. J Gerontol A Biol Sci Med Sci 2009;64:1212-20.
33. Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007; 116:894-900.
34. Ioachimescu AG, Brennan DM, Hoar BM, Hazen SL, Hoogwerf BJ. Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease: a preventive cardiology information system (PreCIS) database cohort study. Arthritis Rheum 2008;58:623-30.
35. Kuo CF, See LC, Luo SF et al. Gout: an independent risk factor for all-cause and cardiovascular mortality. Rheumatology 2010;49:141-6.
36. Miller RE. Urinary system. In: Fowler ME, Mikota SK, eds. Biology, medicine, and surgery of elephants. Oxford: Blackwell Publishing Ltd, 2006:389-92.
37. Andrews P. Evolution and environment in the Hominoidea. Nature 1992;360:641-6.
38. Eaton SB, Konner M. Paleolithic nutrition. N Engl J Med 1985;312:283-9.
39. Krishnan E, Kwoh CK, Schumacher HR, Kuller L. Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension 2007;49: 298-303.
40. Perlstein TS, Gumieniak O, Williams GH et al. Uric acid and the development of hypertension: the Normative Aging Study. Hypertension 2006;48:1031-6.
41. Forman JP, Choi H, Curhan GC. Plasma uric acid level and risk for incident hypertension among men. J Am Soc Nephrol 2007;18:287-92.
42. Brand FN, McGee DL, Kannel WB, Stokes J III, Castelli WP. Hyperuricemia as a risk factor of coronary heart disease: the Framingham Study. Am J Epidemiol 1985;121:11-8.
43. Orowan E. The origin of man. Nature 1955;175:683-4.
44. Sofaer JA, Emery AEH. Genes for super-intelligence? J Med Genet 1981;18:410-3.
45. Vogel W, Brovermen DM, Draguns JG, Klaiber EL. The role of glutamic acid in cognitive behaviours. Psychol Bull 1966;65:367-82.
46. Kasl SV, Brooks GW, Rodgers WL. Serum uric acid and cholesterol in achievement behavior and motivation. I. The relationship to ability, grades, test performance and motivation. JAMA 1970;213:1158-64.
47. Cervini C, Zampa AM. Uric acid and intelligence. Ann Rheum Dis 1982;41:435.
48. Inouye E, Park KS, Asaka A. Blood uric acid level and IQ: a study in twin families. Acta Genet Med Gemellol 1984; 33:237-242.
49. Montoye HJ, Mikkelsen WM. Serum uric acid and achievement in high school. Arthritis Rheum 1973;16: 359-62.
50. Wood B. Origin and evolution of the genus Homo. Nature 1992;355:783-90.
51. Scott GS, Hooper DC. The role of uric acid in protection against peroxynitrite-mediated pathology. Med Hypotheses 2001;56:95-100.
52. Gao X, Chen H, Choi HK, Curhan G, Schwarzschild MA, Ascherio A. Diet, urate, and Parkinson's disease risk in men. Am J Epidemiol 2008;167:831-8.
53. Kim TS, Pae CU, Yoon SJ et al. Decreased plasma antioxidants in patients with Alzheimer's disease. Int J Geriatr Psychiatry 2006;21:344-8.
54. Rentzos M, Nikolaou C, Anagnostouli M et al. Serum uric acid and multiple sclerosis. Clin Neurol Neurosurg 2006; 108:527-31.
55. Keitman D, Ish-Shalom M, Berliner S et al. Low uric acid levels in serum of patients with ALS: further evidence for oxidative stress? J Neurol Sci 2009; 285:95-9.
56. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev 2007;87: 315-424.
57. Squadrito GL, Cueto R, Splenser AE et al. Reaction of uric acid with peroxynitrite and implications for the mechanism of neuroprotection by uric acid. Arch Biochem Biophys 2000;376:333-7.
58. Du Y, Chen CP, Tseng CY, Eisenberg Y, Firestein BL. Astroglia-mediated effects of uric acid to protect spinal cord neurons from glutamate toxicity. Glia 2007;55: 463-72.
59. Zhang W, Doherty M, Bardin T et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65:1312-24.
60. Edwards NL. Febuxostat: a new teatment for hyperuricaemia in gout. Rheumatology 2009;48:ii15-9.